

EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER WITH VERY HIGH VS HIGH PD-L1 EXPRESSION

B. SANCHEZ RODRIGUEZ¹, M. SÁNCHEZ VALERA¹, R. GAZQUEZ PEREZ¹, P. NIETO GUINDO¹, T. MORENO DIAZ¹, D. GAMEZ TORRES¹
¹H.U TORRECÁRDENAS, PHARMACY, ALMERIA, SPAIN.


BACKGROUND AND IMPORTANCE

Pembrolizumab showed **longer overall survival** compared with **chemotherapy** in the first-line treatment of advanced non-small-cell lung cancer (aNSCLC)

AIM AND OBJETIVES To **evaluate** the effectiveness of pembrolizumab in highly expressing patients with aNSCLC, **comparing** patients with PD-L1 expression $\geq 90\%$ (**very high**) vs those with PD-L1 50-89% (**high**) in a tertiary hospital

MATERIAL AND METHODS

- **Observational, retrospective** study.
- **Inclusion criteria:** patients with **NSCLCa** with **pembrolizumab** from August/2018 to August/2022.



VARIABLES

| SEX | AGE | ECOG | SMOKING | PD-L1 EXPRESSION | DATE OF AMINISTRATION |
|-----|-----|------|---------|------------------|-----------------------|
| | | | | | |

RESULTS

- **40 patients** were included, **16 with very high** PD-L1 and **24 with high** PD-L1 expression.
- **73.17%** patients were **male** with median age **43 years** [80-37] and **ECOG=1** [0-2].
- **39.02%** were **current smokers**, **53.65%** were former **smokers** and **4.8%** were **non-smokers**.
- **Median overall survival** in PD-L1(**high**) patients was **16.46 months vs. 21.57 months median overall survival in PD-L1(very high)** patients. $P=0.92$ is obtained from the PD-L1(High) versus PD-L1(very high) survival curves.

CONCLUSION AND RELEVANCE

Survival results in PD-L1 patients ($\geq 90\%$) compared to less expressors were **positive** but without statistically significant differences. It could be due to the small study sample. However, the **median survival obtained is consistent** with data from previous studies, it would be advisable to study this hypothesis in larger cohorts.

